Company / Operating Income per Share
Xenon Pharmaceuticals Inc. Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$4.71
FY2025
5-year range
-$4.71 / -$1.81
FY2021-FY2025
Trend
-31.3%
vs FY2024
Sector context
#167 of 201
Health Care
What the data says
Xenon Pharmaceuticals Inc.'s operating income per share of $-4.71 is lower than 83% of companies in the Health Care sector (FY2025). Operating Income per Share has declined for 5 consecutive years, from $-0.91 in FY2020 to $-4.71 in FY2025.
Based on SEC 10-K filings.
-4.71 in FY2025.
Declined from $-3.20 to $-4.71 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 201This company -$4.71 Sector average -$28.56
▼
+83.5% above sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s operating income per share has declined for 5 consecutive years.
- In FY2025, operating income per share decreased 31.3% year-over-year.
- Ranks #167 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.71 | -31.3% |
| FY2024 | -$3.59 | -12.0% |
| FY2023 | -$3.20 | -50.0% |
| FY2022 | -$2.13 | -17.8% |
| FY2021 | -$1.81 | -99.8% |
| FY2020 | -$0.91 | +45.1% |
| FY2019 | -$1.65 | +21.9% |
| FY2018 | -$2.11 | -304.8% |
| FY2017 | -$0.52 | +69.7% |
| FY2016 | -$1.73 | -161.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026